EICHORPublic-registry site landscape for NCT01121120, “Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients”, a Lymphoma, Non-Hodgkin study sponsored by Tarix Pharmaceuticals. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT01121120 (registry record) |
| Study title | Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant (PBSC) in Hodgkin, Non-Hodgkin Lymphoma or Multiple Myeloma Patients |
| Official title | Phase II Study Evaluating the Safety and Efficacy of TXA127 in the Acceleration of Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant in Patients With Hodgkin Lymphoma, Non-Hodgkin Lymphoma or Multiple Myeloma Undergoing Limited Reinfusion of CD34+ Cells |
| Sponsor | Tarix Pharmaceuticals |
| Condition(s) | Lymphoma, Non-Hodgkin; Hodgkin Disease; Multiple Myeloma |
| Phase | PHASE2 |
| Listed sites | 10 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT01121120.
Eichor generates a preliminary site-risk snapshot for NCT01121120 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Lymphoma, Non-Hodgkin trials
← Eichor home · All tracked trials · Lymphoma, Non-Hodgkin studies · Weekly briefs
